NEWS
View news from our Featured Companies.
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Encinitas, California--(September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study of KIO-301. KIO-301 is A molecular photoswitch being evaluated in a Phase 1B...
Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Encinitas, California--(September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of...
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
ENGLEWOOD, CO / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the...
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
CARMEL, Ind., Sept. 13, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that...
NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS
CARMEL, Ind., Sept. 12, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
ContraPest® Deploying at Waste Water Treatment Facilities
PHOENIX, Sept. 11, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that...
LiqTech to Participate in Two Upcoming Investor Conferences in September 2023
BALLERUP, Denmark, Sept. 7, 2023 -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company that manufactures and markets highly specialized filtration products and systems, announced today that Fei Chen, CEO, Simon Stadil, CFO, and Tobias Baldrian...
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 07, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
IRADIMED CORPORATION to Participate at Upcoming Investor Conferences
WINTER SPRINGS, Fla., Sept. 06, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences. Iradimed management is scheduled to participate in investor meetings at the H.C....
Mogo to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), one of Canada's leading financial technology companies, today announced that Greg Feller, President, will be participating in the H.C. Wainwright 25th Annual Global Investment...
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla., Sept. 5, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood...
InfuSystem to Participate in Lake Street’s 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced...
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Encinitas, California--(September 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "Special Meeting") held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and...
Mogo Regains Compliance with Nasdaq Minimum Bid Price Requirement
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), one of Canada's leading financial technology companies, today announced that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company...
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
NEW YORK, Aug. 30, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients...
Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Live Event to be Held Thursday, August 31, at 7:30 pm Eastern TimeEncinitas, California--(August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and...
SenesTech Announces Closing of Warrant Exercise for $2.1 Million in Gross Proceeds
Isolate Bait System™ Now Shipping PHOENIX, Aug. 29, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats,...
ImmuCell Announces Submission of CMC Technical Section to the FDA
PORTLAND, Maine, Aug. 29, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
Zoomd Technologies Reports Second Quarter 2023 Financial Results and Management Update
Conference call will be held on August 29, 2023, at 11AM ET VANCOUVER, BC, Aug. 29, 2023 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech)...
NeurAxis Highlights Pediatric Post-Concussion Clinical Study
CARMEL, Ind., Aug. 29, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted A...
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
PONTE VEDRA, Fla., Aug. 28, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in...
Mogo Files Early Warning Report
VANCOUVER, British Columbia - This news release is issued by Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company") pursuant to the early warning requirements of Canada's National Instrument 62-104 and National Instrument 62-103 with respect to common shares...
NeurAxis Highlights Strength of its Board of Directors
CARMEL, Ind., Aug. 24, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the...
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide...
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Encinitas, California--(August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal,...